Absorbed dose estimation of some 99mTc-hepatobiliary agents.

Area of Science:

• Nuclear medicine
• Radiopharmacology
• Medical imaging

Background:

• Hepatobiliary agents are crucial for diagnosing liver and bile duct conditions.
• 131I-Rose-Bengal has been a standard, but its radiation dose requires consideration.
• Development of novel agents aims to improve safety and efficacy in diagnostic imaging.

Purpose of the Study:

• To compare the absorbed radiation dose of new 99mTc-labeled hepatobiliary agents with 131I-Rose-Bengal.
• To evaluate the safety profile of five 99mTc-Pyridoxal amino acid complexes and 99mTc-HIDA.
• To determine the suitability of these new agents for human administration.

Main Methods:

• Estimation of absorbed radiation doses to various organs in humans.
• Administration of six new hepatobiliary agents: five 99mTc-Pyridoxal amino acid complexes and 99mTc-HIDA.
• Comparative analysis with radiation dose data from 131I-Rose-Bengal.

Main Results:

• The new 99mTc-agents resulted in significantly lower radiation doses to the total body compared to 131I-Rose-Bengal.
• Radiation doses to the gonads were also significantly reduced with the 99mTc-agents.
• The critical organ, the upper part of the large intestine, showed substantially lower absorbed doses with the new agents.

Conclusions:

• The novel 99mTc-Pyridoxal amino acid complexes and 99mTc-HIDA demonstrate a superior safety profile regarding radiation exposure.
• Significantly lower radiation doses to critical organs and the body make these agents a safer alternative.
• These 99mTc-based hepatobiliary agents are suitable for safe application in human diagnostic procedures.